Intrepid Family Office’s Filana Therapeutics FLNA Stock Holding History

Intrepid Family Office’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$23.6K	–	41
2024 Q4	$23.6K	Buy	+10,000	New	+$176K	0.02%	35
2023 Q3	$208K	Sell	12,500 -2,500	-17%	-$49.5K	0.33%	28
2023 Q2	$368K	Hold	15,000	–	–	0.7%	23
2023 Q1	$360K	Sell	15,000 -10,000	-40%	-$277K	0.79%	21
2022 Q4	$723K	Hold	25,000	–	–	1.81%	17
2022 Q3	$1.05M	Hold	25,000	–	–	3.17%	11
2022 Q2	$703K	Sell	25,000 -10,000	-29%	-$253K	1.82%	15
2022 Q1	$1.3M	Buy	35,000 +1,600	+5%	+$67.8K	2.12%	19
2021 Q4	$1.46M	Buy	+33,400	New	+$1.75M	1.66%	23

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Intrepid Family Office's FLNA Position: Q1 2025 in Review

Intrepid Family Office sold out of Filana Therapeutics (FLNA) in Q1 2025, closing a stake of 10,000 shares — an estimated $23.6K sold.

Intrepid Family Office first reported a position in FLNA in Q4 2021 and held it in 9 quarters. The position peaked at $1.46M in Q4 2021. 117 funds tracked by Wall St. Rank hold FLNA as of Q1 2025.

Intrepid Family Office reported no remaining Filana Therapeutics position as of Q1 2025 after selling out during the quarter.
Intrepid Family Office sold 10,000 Filana Therapeutics shares in Q1 2025, an estimated $23.6K.
Intrepid Family Office first reported a position in Filana Therapeutics in Q4 2021 and held it in 9 quarters.
Intrepid Family Office's Filana Therapeutics position peaked at $1.46M in Q4 2021.
117 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2025.

Based on Intrepid Family Office's 13F filing for Q1 2025, filed 15 May 2025.